Welcome to our dedicated page for VERADERMICS SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERADERMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERADERMICS's regulatory disclosures and financial reporting.
Veradermics, Inc director John W. Childs, through the John W. Childs 2013 Revocable Trust, indirectly bought 294,117 shares of Common Stock at $17.00 per share in an open‑market purchase. This amended Form 4 corrects the earlier report by clarifying that the shares are held via the revocable trust rather than J.W. Childs Associates (FL), L.P.
Veradermics, Incorporated disclosed that venture funds affiliated with Longitude Capital and managing members Patrick G. Enright and Juliet Tammenoms Bakker have filed a Schedule 13D reporting a significant stake in its common stock. The Reporting Persons beneficially own 4,653,873 shares of common stock, representing 12.5% of the outstanding shares based on 37,339,464 shares outstanding as of February 5, 2026.
Longitude Venture Partners V, L.P. holds 2,600,399 shares, and Longitude 103.8 East, L.P. holds 2,053,474 shares, with voting and dispositive power shared through their general partners. These positions arose from investments in Veradermics’ Series B and Series C preferred stock and additional common shares purchased at $17.00 per share in the initial public offering. The investors state they hold the shares for general investment purposes, may increase or decrease their holdings over time, and are subject to a 180‑day lock-up following the IPO underwriting agreement.
Veradermics, Inc. received a new major shareholder disclosure from Viking Global–affiliated funds. The group reports beneficial ownership of 2,151,493 shares of Veradermics common stock, representing 5.8% of the outstanding shares following the company’s initial public offering.
The position is held through two main Cayman Islands limited partnerships: Viking Global Opportunities Illiquid Investments Sub-Master LP with 1,290,896 shares and Viking Global Opportunities Drawdown (Aggregator) LP with 860,597 shares. Various Delaware general partner and management entities, including Viking Global Investors LP and Viking Global Opportunities Parent GP LLC, are listed as having shared voting and dispositive power.
Individuals O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are each reported as beneficial owners of the full 2,151,493 shares through their roles on Viking’s executive committee, with no direct share ownership. The filing certifies that the securities were not acquired to change or influence control of Veradermics.
Suvretta Capital Management and affiliated Averill funds filed a Schedule 13D reporting significant ownership in Veradermics, Inc. common stock following its initial public offering. Suvretta Capital and Aaron Cowen may be deemed to beneficially own 4,168,991 shares, representing 11.9% of the common stock, based on 35,077,084 shares outstanding as indicated in the Final Prospectus on February 4, 2026.
The position was built through private purchases of Series B and Series C preferred stock in 2024 and 2025, which converted into common shares at a 1-for-10.067 ratio, plus substantial purchases in the initial offering at $17.00 per share and subsequent open-market buys.
The funds state they hold Veradermics for investment purposes but may buy more or sell shares depending on factors such as business prospects and market conditions. They benefit from investor registration rights and are subject to lock-up agreements restricting transfers for 180 days after February 3, 2026.
SR One Capital–affiliated funds filed a Schedule 13D disclosing a 6.4% stake in Veradermics, Inc. common stock. The funds collectively own 2,401,868 shares of Veradermics’ Common Stock following the company’s initial public offering of 17,339,294 shares at $17.00 per share.
SR One Fund II Aggregator holds 1,621,121 shares and AMZL holds 780,747 shares, largely from the automatic conversion of Series C preferred stock at a 10.067‑for‑1 ratio plus IPO purchases. The filing states the shares were acquired for investment purposes, using fund working capital without borrowing, and outlines registration rights and a 180‑day IPO lock‑up restricting sales and hedging transactions.
Veradermics, Inc. reported multiple insider share purchases by major holders linked to Suvretta Capital Management, LLC over several days in early February 2026. These indirect open‑market transactions involved common stock at prices in the mid‑$30s per share.
On February 4, 2026, reported indirect purchases included 53,344 shares of common stock at $37.11 per share, bringing one reported indirect position to 3,604,141 shares. Additional indirect buys continued on February 5 and 6, 2026, including 19,338 shares at $36.55 per share, after which one indirect holding stood at 520,453 shares.
Suvretta Capital Management, LLC and affiliated reporting persons disclosed their initial insider holdings in Veradermics, Inc. common stock. As of February 4, 2026, they indirectly beneficially owned 3,515,458 shares of common stock and an additional 370,859 shares, both reported as indirect ownership.
The filing is an initial statement of beneficial ownership, not a report of new share purchases or sales.
Veradermics, Inc. director Katarina Pance received a grant of stock options for 43,000 shares of common stock on February 3, 2026. The options carry an exercise price of $17 per share and are held as a direct ownership position.
The award was reported as an acquisition under a grant or award transaction code. According to the terms, the option will become fully vested and exercisable on February 3, 2027, which is the first anniversary of the vesting commencement date.
Veradermics, Inc. director Jane M. Grant-Kels reported acquiring equity through an option grant and a preferred stock conversion. On February 3, 2026, she received a stock option for 51,525 shares of common stock at an exercise price of $17 per share, which will be fully vested and exercisable on February 3, 2027.
On February 5, 2026, 2,455 shares of Series A Convertible Preferred Stock automatically converted into 2,455 shares of common stock on a 10.067-for-1 basis, without additional payment, immediately before the closing of Veradermics’ initial public offering, leaving her with 2,455 common shares held directly.
Veradermics, Inc. reported that director David Matthew Friedman was granted a stock option covering 43,000 shares of common stock at an exercise price of $17 per share on February 3, 2026. The option is scheduled to become fully vested and exercisable on February 3, 2027.
According to the disclosure, Friedman, an employee of Suvretta Capital Management, LLC, is holding this award for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. He disclaims beneficial ownership of the option, while the Funds and Suvretta Capital may be deemed to have an indirect pecuniary interest through rights to receive director compensation linked to his board service.